Desonide

Summary

Desonide (CHEMBL1201109) is an approved small-molecule anti-inflammatory drug (ATC S01BA11); indicated across 3 conditions including eye disorder and atopic eczema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01BA11 (+1 more)
• Indications: 3 conditions
• Clinical trials: 7
• Chemistry: 416.5 Da · C24H32O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201109
Name	Desonide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5311066
ChEBI	CHEBI:204734
ATC	S01BA11, D07AB08
Molecular formula	C24H32O6
Molecular weight	416.5
InChIKey	WBGKWQHBNHJJPZ-LECWWXJVSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O

IUPAC name: (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

ChEBI definition: Triamcinolone acetonide with hydrogen instead of the fluorine substituent at position 9. A corticosteroid anti-inflammatory, it is used topically as a cream, ointment or lotion for the treatment of various skin disorders.

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: D-2083, D2083, Desonate, Desonida, Desonide, Desonide component of tridesilon, Desowen, NSC-759226, Tridesilon, Verdeso, DESONIDE, apolar

Patent coverage: 6,159 distinct patent families (23,805 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Glucocorticoid receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	7.8	AC50	16	nM	CHEMBL_ACT_25175421
PGR	7.19	AC50	65	nM	CHEMBL_ACT_25222668

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0005752
atopic eczema	4	MONDO:0004980	EFO:0000274
skin disorder	4	MONDO:0005093	EFO:0000701

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01542138	PHASE4	COMPLETED	Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation
NCT02624544	PHASE4	WITHDRAWN	Proton Pump Inhibitors Use in Patients With Psoriasis
NCT01467362	PHASE3	COMPLETED	Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
NCT02286700	PHASE3	UNKNOWN	Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis
NCT03386032	PHASE3	COMPLETED	8-Week Atopic Dermatitis (AD) Treatment Study
NCT03437005	PHASE1	RECRUITING	Alternation in the Human Microbiome With Commonly Used Topical Medications
NCT03758365	PHASE1	COMPLETED	Evaluation of the Vasoconstriction Properties of MC2-01 Cream

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).